MenCaps Patch

Manufacturer
Alexso Inc
Effective date
2019-02-12
Label type
HUMAN OTC DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 22:58:32

Label at a glance#

ProductMenCaps
Active ingredientCAPSAICIN, MENTHOL, UNSPECIFIED FORM
Label structure12 sections

Indications and uses

For temporary relief of minor aches & pains of muscles & joints associated with arthritis, simple backache, strains, bruises, and sprains.

Dosage and administration

Adults and children 12 years and over: Apply 1 patch to the affected area of intact skin up to 3 times a day. Do not leave patch on for more than 8 hours at a time. Instructions for Use: • Clean and dry the affected area. • Open pouch and remove one patch. • Remove any protective film and apply directly to affected area of pain. Apply immediately after removal from the protective envelope. • Wash hands with soap a...

Label contents#

Full prescribing information#

Active ingredients:

OTC - ACTIVE INGREDIENT SECTION

Menthol 4.5%

Purpose

OTC - PURPOSE SECTION

Topical Analgesic

Active ingredients:

OTC - ACTIVE INGREDIENT SECTION

Capsaicin 0.0225%

Purpose

OTC - PURPOSE SECTION

Topical Anesthetic

Uses:

INDICATIONS & USAGE SECTION

For temporary relief of minor aches & pains of muscles & joints associated with arthritis, simple backache, strains, bruises, and sprains.

Directions:

DOSAGE & ADMINISTRATION SECTION

Adults and children 12 years and over: Apply 1 patch to the affected area of intact skin up to 3 times a day. Do not leave patch on for more than 8 hours at a time.

Instructions for Use:

  • Clean and dry the affected area.
  • Open pouch and remove one patch.
  • Remove any protective film and apply directly to affected area of pain.
    Apply immediately after removal from the protective envelope.
  • Wash hands with soap and water after handling the patches.
  • Reseal pouch containing unused patches after each use. Do not store patch outside the sealed envelope.
  • Discontinue use at least 1 hour before a bath or shower and do not use immediately after a bath or shower.
  • Fold used patches so that the adhesive side sticks to itself and safely discard used patches or pieces of cut patches where children and pets cannot get to them.

Warnings:

WARNINGS SECTION

  • For external use only. Use only as directed or by a health professional.
  • Do not use: On wounds, cuts, damaged or infected skin.
                    -  On eyes, mouth, genitals, or any other mucus membranes.
  • Stop and consult your physician if pregnant or if pain worsens
  • Allergy Alert: if you are allergic to any ingredients of this product or chili peppers contact a doctor before use.

Keep out of reach of children.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Consult physician for children under 12.

Other Ingredients:

INACTIVE INGREDIENT SECTION

Water, Glycerol, Sodium Polyacrylate, Polysorbate 80, Citrus Medica Limonum (Lemon) Peel Oil, Aloe Barbadensis Leaf (Aloe Vera Gel) Juice, EDTA Disodium salt, Diazolidinyl Urea, Methylparaben, Iodopropynyl Butylcarbamate, Propylparaben.

Questions or Comments

OTC - QUESTIONS SECTION

Call 888.495.6078

PACKAGE INSERT

PATIENT MEDICATION INFORMATION SECTION

Patient Information

(updated 6/2015)

Read the patient information sheet provided before you start using this medication and each time you get a refill. If you have any questions, please consult your doctor or pharmacist. Inform your doctor if your condition does not improve or if it worsens.

This information may not include all of the information needed to use MenCaps Patch® safely and effectively.

For Topical Use Only

What is MenCaps Patch®?

This is a topical patch consisting of the topical analgesic, menthol, and the topical analgesic, capsaicin extract.

What is MenCaps Patch® used for?

The patch is applied to the skin assisting patients in the management of mild to moderate acute or moderate aches or pain of muscles and joints associated with arthritis, backache, strains and sprains. The diagnosis of acute or chronic topical pain can be made relatively simply by the diagnostic practitioner, however uncovering the underlying pathology manifesting as pain and discomfort is often more difficult.

The combination of capsaicin and menthol is a highly effective combination of working synergistically to ease the discomfort while the root cause is being managed and treated by your healthcare team.

DO NOT USE:

OTC - DO NOT USE SECTION

  • If you are allergic to any of the ingredients in this product
  • On wounds or damaged skin
  • With a heating pad
  • Concurrently with any other external pain-relieving products

What are the possible side effects with MenCaps Patch®

  • Common (≥10%): itching, redness or flaking of the skin following application (note: the majority of patients experience no significant adverse events following patch application).
  • NOTE: serious side effects are, in general, related to accidental toxicity of medication by applying considerably more than directed by your doctor or pharmacist
  • Tell your healthcare provider about all the medicines you take. This includes prescription and nonprescription medicines, vitamins, and herbal supplements

WARNINGS:

WARNINGS AND PRECAUTIONS SECTION

  1. Do not use:
  2. On wounds, cuts, damaged or infected skin
  3. On eyes, mouth, genitals, or other mucous membranes
  4. Consult physician for children under 12 years of age
  5. Stop and consult your prescriber if pain worsens
  6. DISCONTINUE USE AT LEAST 1 HOURS BEFORE A BATH OR SHOWER AND DO NOT USE IMMEDIATELY AFTER A BATH OR SHOWER

Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you:

  • Shortness of breath
  • Swelling or numbness of the tongue or throat
  • Severe headache or vomiting
  • Dizziness or faintness
  • Changes in vision or speech

This is not a complete list of the possible side effects. For more information, talk with your doctor or pharmacist. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DIRECTIONS FOR USE:

INSTRUCTIONS FOR USE SECTION

Adults and children 12 years and over: Apply 1 patch to the affected area of intact skin up to 3 times a day. MenCaps Patch® should not be left on for more than 8 hours at a time.

  1. Clean and dry the affected area.
  2. Open pouch and remove one patch.
  3. Remove any protective film and apply directly to the painful area. Apply immediately after opening.
  4. Wash hands with soap and water after handling the patches.
  5. Reseal pouch containing unused patches after each use. Do not store patch outside the sealed envelope.
  6. Fold used patches so that the adhesive side sticks to itself. Next, safely discard the used patches or pieces of cut patches where children and pets cannot get to them.

Children under 12 years of age:

  • Consult a doctor.

General information about the safe and effective use
MenCaps Patch®

Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use this product for another indication. Your doctor has prescribed this drug for you and you alone. Do not give this drug to anyone else, even if they have the same condition.

How should I store MenCaps Patch®

Store product at room temperature at 68°F to 77°F (20°C to 25°C). Keep away from heat and sunlight. Protect from excessive moisture. Discard product after expiration date posted on the product label.

DO NOT use the product after the expiration date printed on the box.

KEEP OUT OF REACH OF CHILDREN

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

This leaflet provides the most important information about MenCaps Patch®. If you would like more information, talk with your healthcare provider or pharmacist. There is additional information in the following sections intended for healthcare professionals.

What are the active ingredients in MenCaps Patch®?

The patch consists of 4.5% menthol and 0.0225% capsaicin.

INACTIVE INGREDIENTS:

INACTIVE INGREDIENT SECTION

Water                                                       Aloe Barbadesis Leaf (Aloe Vera Gel)
Glycerol                                                   EDTA Disodium salt
Sodium Polyacrylate                                 Diazolidinyl Urea
Polysorbate 80                                         Methylparaben
Propylparaben                                          Citrus Medica Limonum
Iodopropynyl Butylcarbamate                  (Lemon) Peel Oil

PRESCRIBER INFORMATION

SPL UNCLASSIFIED SECTION

MenCaps Patch® (Menthol 4.5% / Capsaicin 0.0225% Topical Patch)

DESCRIPTION:

DESCRIPTION SECTION

MenCaps Patch® is an OTC topical patch containing 15 articulated MenCaps patches (5 per re-sealable pouch x 3 pouches). Capsaicin is present in a 0.0225% concentration (w/w). It is chemically designated as (E)-N-[(4-Hydroxy-3-methoxyphenyl) methyl]-8- methylnon-6-enamide and has an empirical formula of C18H27NO3. The molecular weight of capsaicin is 305.41 g/mol. Menthol is present in a 4.5% concentration (w/w). The chemical name is (1R,2S,5R)-2- isopropyl-5-methylcyclohexanol. The empirical formula for menthol is C10H20O with a molecular weight of 156.27 g/mol.

The structural formulas are:

Box Label
Box Label

CLINICAL PHARMACOLOGY:

SPL UNCLASSIFIED SECTION

Capsaicin is an active component of chili peppers known clinically as a rubefacient. It acts as a counter-irritant by producing heat when in contact with human tissue. Mechanistically, capsaicin exerts its analgesic and anti-inflammatory effects by mimicking a burning sensation – whereby overwhelming the nerves by calcium influx, thereby rendering the nerves unable to signal a pain response for an extended period of time. With repeated exposure, the neurons become depleted of neurotransmitters –specifically substance P - leading to a reduction in the sensation of pain and the blockade of neurogenic inflammation. This process is reversed when the capsaicin is discontinued.

Menthol has local anesthetic and counterirritant qualities, and it also acts as a weak kappa (κ) opioid receptor agonist. Menthol acts to chemically trigger the cold-sensitive TRPM-8 receptors in the skin - responsible for the well-known cooling sensation it stimulates when applied directly to the skin. Menthol's analgesic properties are not fully understood, however they are mediated through a selective activation of κ-opioid receptors. Menthol also blocks voltage-sensitive sodium channels, reducing neural activity that may stimulate muscle tissue.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

MenCaps Patch® is a formulation used to assist patients for the temporary relief of minor aches & pains of muscles & joints associated with arthritis, simple backache, strains, bruises, and sprains. Peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, may also be symptomatically improved using this patch if recommended by the healthcare team.

Other uses may be considered if deemed clinically relevant.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Known hypersensitivity to menthol, capsaicin, or any of the inactive ingredients listed above.

WARNINGS:

  1. Do not use on wounds, cuts, damaged or infected skin
  2. Do not use on eyes, mouth, genitals, or any other mucous membranes
  3. Keep out of reach of children

PRECAUTIONS:

PRECAUTIONS SECTION

Because of the possibility of sedation, patients should be cautioned regarding the operation of serious machinery or automobiles, and activities made hazardous by decreased alertness.

DRUG INTERACTIONS:

SPL UNCLASSIFIED SECTION

No Drug interactions have been assessed with MenCaps Patch®

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY:

SPL UNCLASSIFIED SECTION

Nonclinical toxicity studies to determine the potential of this topical preparation to cause carcinogenicity or mutagenicity have not been performed. The effect of the product on fertility has not been evaluated in animals.

PREGNANCY:

OTC - PREGNANCY OR BREAST FEEDING SECTION

The safety of MenCaps Patch® has not been established during pregnancy. There are no well-controlled studies in pregnant women.

PEDIATRIC / GERIATRIC USE:

SPL UNCLASSIFIED SECTION

Safety and effectiveness in pediatric and geriatric patients have not been established.

NURSING MOTHERS:

SPL UNCLASSIFIED SECTION

The effect of MenCAps Patch® on the nursing infant has not been evaluated.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The most common adverse reactions are application site reactions, including dermatitis, itching or scaling. These tend to be dose-limiting and diminish with time.

Serious adverse experiences following the administration of MenCaps Patch® are similar in nature to those observed in other amide anesthetic-containing agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption, or may result from hypersensitivity, idiosyncrasy, or a diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature.

OVERDOSAGE:

OVERDOSAGE SECTION

There have been no reports of over-dosage with MenCaps Patch®. Signs of overdosage would include vomiting, drowsiness, coma, respiratory depression, and seizures. In the case of an overdosage, discontinue the product immediately, treat the patient symptomatically, and institute supportive measures.

STORAGE:

STORAGE AND HANDLING SECTION

Store at room temperature at 68°F to 77°F (20°C to 25°C). Keep away from heat or sunlight. Protect from excessive moisture. The product can be considered safe and effective to use when maintained under these recommended conditions within the posted expiration date.

HOW SUPPLIED:

MenCaps Patch® is supplied in the following dosage form:

  • 15 Articulated Patches [(5 per Re-sealable Pouch) x 3]

Manufactured for : Alexso Inc
2317 Cotner Ave • Los Angeles, CA 90064
www.alexso.com • 888.495.6078

NDC: 50488-1701-1 Size: 15 Patches

Package/Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 50488-1701-1

MenCaps

Patch

Qty: 15 Patches

(5 per Resealable Pouch) x 3

Box Label
Box Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1658663capsaicin 0.0225 % / menthol 4.5 % Medicated PatchPSN4
1658663capsaicin 0.000225 MG/MG / menthol 0.045 MG/MG Medicated PatchSCD4
1658663capsaicin 0.0225 % / menthol 4.5 % Medicated PatchSY4

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
473d070d-1c38-488e-b991-c4d1bf45aab8Product name120210201

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
50488-1701-12024-01-30C16284748780-11030e365-579b-111a-e063-dadaa90a10e2MenCaps Patch

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50488-1701-1MenCaps3 in 1 BOXPATCH34
50488-1701-1MenCaps5 in 1 POUCHPATCH54

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50488-1701MENCAPS (CAPSAICIN AND MENTHOL) PATCH [ALEXSO INC]4Legacy NDC, 2 package rows20190214_09299ae8-ab15-4291-ab51-f476c9e2f0fd.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50488-1701-1EA - Each50488-17013b89fca1-a6ed-4ff8-8329-c733ec589f4612015-08-04

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CAPSAICINACTIVE INGREDIENTS07O44R1ZM2
MENTHOLACTIVE INGREDIENTL7T10EIP3A2
CAPSAICINACTIVE MOIETYS07O44R1ZM2
MENTHOLACTIVE MOIETYL7T10EIP3A2
ALOE VERA LEAFINACTIVE INGREDIENTZY81Z83H0X2
DIAZOLIDINYL UREAINACTIVE INGREDIENTH5RIZ3MPW42
EDETATE DISODIUMINACTIVE INGREDIENT7FLD91C86K2
GLYCERININACTIVE INGREDIENTPDC6A3C0OX2
IODOPROPYNYL BUTYLCARBAMATEINACTIVE INGREDIENT603P14DHEB2
LEMON PEELINACTIVE INGREDIENT72O054U6282
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T2
POLYSORBATE 80INACTIVE INGREDIENT6OZP39ZG8H2
PROPYLPARABENINACTIVE INGREDIENTZ8IX2SC1OH2
SODIUM POLYACRYLATE (8000 MW)INACTIVE INGREDIENT285CYO341L2
WATERINACTIVE INGREDIENT059QF0KO0R2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 15 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50488-170150488-1701-1

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 13 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 7 · 380 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
GLYCERINGLYCERINPDC6A3C0OXTABLET / PERIODONTAL0.53 mgExact identifier — unii candidate
75 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KEMULSION / TOPICAL0.11 %w/wExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INFILTRATION6 mgExact identifier — unii candidate
77 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION / PERIDURAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHOINTMENT / TOPICAL0.2 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHCREAM / TOPICAL6 mgExact identifier — unii candidate
68 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HEMULSION / OPHTHALMIC26 mgExact identifier — unii candidate
78 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HPOWDER / ORAL66 mgExact identifier — unii candidate
78 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION/ DROPS / OPHTHALMIC0.13 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSUPPOSITORY / RECTAL440 mgExact identifier — unii candidate
75 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUPPOSITORY / VAGINALNAExact identifier — unii candidate
68 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXCONCENTRATE / ORAL1800 mgExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSUSPENSION / ORAL26208 mgExact identifier — unii candidate
75 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR0.4 mgExact identifier — unii candidate
68 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXTABLET, EXTENDED RELEASE / ORAL7 mgExact identifier — unii candidate
75 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXLOTION / TOPICAL3990 mgExact identifier — unii candidate
75 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KGEL / TRANSDERMAL1 mgExact identifier — unii candidate
77 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HSUSPENSION, EXTENDED RELEASE / ORAL40 mgExact identifier — unii candidate
78 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / RESPIRATORY (INHALATION)43 mgExact identifier — unii candidate
77 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSPONGE / TOPICAL2 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HINJECTION, SUSPENSION / INTRAMUSCULAR4 mgExact identifier — unii candidate
78 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCREAM, AUGMENTED / TOPICAL2 mgExact identifier — unii candidate
77 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXINJECTION, SOLUTION / SUBCUTANEOUS15 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HOINTMENT / TOPICAL0.1 %w/wExact identifier — unii candidate
78 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TSOLUTION / OPHTHALMIC0.05 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR3.6 mgExact identifier — unii candidate
79 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRA-ARTICULAR0.05 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HAEROSOL, FOAM / TOPICAL0.98 %w/wExact identifier — unii candidate
78 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXTABLET, CHEWABLE / ORAL12 mgExact identifier — unii candidate
75 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HINJECTION, SOLUTION, CONCENTRATE / INTRAVENOUS4739 mgExact identifier — unii candidate
78 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION/ DROPS / OPHTHALMIC0.01 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSYSTEM / IONTOPHORESIS0.1 mgExact identifier — unii candidate
77 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHJELLY / TOPICAL180 mgExact identifier — unii candidate
68 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TFILM / BUCCAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TGRANULE, FOR SUSPENSION / ORAL80 mgExact identifier — unii candidate
79 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HENEMA / RECTAL0.01 %w/vExact identifier — unii candidate
78 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHFILM / BUCCAL0.22 mgExact identifier — unii candidate
68 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / RECTAL97 mgExact identifier — unii candidate
77 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TENEMA / RECTAL0.18 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HTABLET, COATED / ORAL18 mgExact identifier — unii candidate
78 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSPRAY / NASAL0.2 mgExact identifier — unii candidate
68 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KCREAM / VAGINAL3 mgExact identifier — unii candidate
77 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TEMULSION / TOPICAL0.2 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HINJECTION, SUSPENSION / INTRAVITREAL0.02 %w/vExact identifier — unii candidate
78 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TJELLY / TOPICAL420 mgExact identifier — unii candidate
79 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXLIQUID / ORAL2400 mgExact identifier — unii candidate
75 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HTABLET / SUBLINGUAL0.08 mgExact identifier — unii candidate
78 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUSPENSION/ DROPS / OPHTHALMIC0.01 %w/wExact identifier — unii candidate
68 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KTABLET, FILM COATED / ORAL4 mgExact identifier — unii candidate
77 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / RECTAL0.02 %w/vExact identifier — unii candidate
68 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / TOPICAL24 mgExact identifier — unii candidate
68 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXDROPS / ORAL300 mg/1mlExact identifier — unii candidate
75 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSOLUTION / NASAL140 mgExact identifier — unii candidate
68 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HSUSPENSION / AURICULAR (OTIC)1 %w/vExact identifier — unii candidate
78 equally ranked IID candidates
METHYLPARABENMETHYLPARABENA2I8C7HI9TCAPSULE, EXTENDED RELEASE / ORAL2 mgExact identifier — unii candidate
79 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRAMUSCULAR10 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
POLYSORBATE 80POLYSORBATE 806OZP39ZG8HSUPPOSITORY / RECTAL72.15 mgExact identifier — unii candidate
78 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXCLOTH / TOPICAL0.05 mg/mgExact identifier — unii candidate
75 equally ranked IID candidates
PROPYLPARABENPROPYLPARABENZ8IX2SC1OHSUSPENSION / RECTAL271 mgExact identifier — unii candidate
68 equally ranked IID candidates
GLYCERINGLYCERINPDC6A3C0OXSUSPENSION / AURICULAR (OTIC)0.05 %w/wExact identifier — unii candidate
75 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
7ba331f7-2b5d-431d-bef4-8a427c564fad09299ae8-ab15-4291-ab51-f476c9e2f0fd2019-02-12Warnings, Adverse reactionsExact identifier
spl id: 7ba331f7-2b5d-431d-bef4-8a427c564fad
spl set id: 09299ae8-ab15-4291-ab51-f476c9e2f0fd

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.